Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Eyepoint Pharmaceuticals received an average consensus rating of "Moderate Buy" from eight analysts, with one sell rating and seven buy ratings.
• The company's shares opened at $13.34 and have a market capitalization of approximately $919.53 million, with a price-to-earnings ratio of -4.98.
• Eyepoint's recent earnings report showed a loss of ($0.85) per share, missing estimates and highlighting a negative net margin of 337.93%.

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $26.8571.

A number of brokerages have recently weighed in on EYPT. Chardan Capital reaffirmed a "buy" rating and set a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. HC Wainwright lifted their price target on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Royal Bank Of Canada initiated coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 price target for the company. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, October 8th.

Eyepoint Pharmaceuticals Trading Down 1.7%

Shares of EYPT opened at $13.34 on Tuesday. The firm's 50-day moving average price is $12.53 and its 200-day moving average price is $9.39. The firm has a market capitalization of $919.53 million, a price-to-earnings ratio of -4.98 and a beta of 1.95. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $14.91.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.18). The company had revenue of $5.33 million for the quarter, compared to the consensus estimate of $6.82 million. Eyepoint Pharmaceuticals had a negative net margin of 337.93% and a negative return on equity of 63.80%. On average, research analysts forecast that Eyepoint Pharmaceuticals will post -2.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. lifted its position in Eyepoint Pharmaceuticals by 9.7% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company's stock valued at $63,988,000 after acquiring an additional 600,000 shares during the period. Federated Hermes Inc. lifted its position in Eyepoint Pharmaceuticals by 12.6% during the 2nd quarter. Federated Hermes Inc. now owns 4,599,450 shares of the company's stock valued at $43,281,000 after acquiring an additional 513,870 shares during the period. Franklin Resources Inc. lifted its position in Eyepoint Pharmaceuticals by 3.6% during the 2nd quarter. Franklin Resources Inc. now owns 4,301,123 shares of the company's stock valued at $40,474,000 after acquiring an additional 151,262 shares during the period. Vanguard Group Inc. lifted its position in Eyepoint Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 3,834,368 shares of the company's stock valued at $20,782,000 after acquiring an additional 31,141 shares during the period. Finally, Aberdeen Group plc raised its holdings in Eyepoint Pharmaceuticals by 346.9% in the second quarter. Aberdeen Group plc now owns 1,031,201 shares of the company's stock worth $9,704,000 after buying an additional 800,456 shares during the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.